Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
2,380
Views
11
CrossRef citations to date
0
Altmetric
Editorial

Secreted calreticulin mutants subvert anticancer immunosurveillance

Peng Liua Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;b Cell Biology and Metabolomics platforms, Gustave Roussy Cancer Campus, Villejuif, France;c UMR1138, INSERM, Paris, France;d Sorbonne Paris Cité, Université Paris Descartes, Paris, France;e Université Pierre et Marie Curie, Paris, France;f Faculty of Medicine, Paris Sud/Paris XI University, Le Kremlin-Bicêtre, FranceORCID Iconhttps://orcid.org/0000-0002-1682-9222
ORCID Icon,
Liwei Zhaoa Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;b Cell Biology and Metabolomics platforms, Gustave Roussy Cancer Campus, Villejuif, France;c UMR1138, INSERM, Paris, France;d Sorbonne Paris Cité, Université Paris Descartes, Paris, France;e Université Pierre et Marie Curie, Paris, France;f Faculty of Medicine, Paris Sud/Paris XI University, Le Kremlin-Bicêtre, FranceORCID Iconhttps://orcid.org/0000-0001-5077-327X
ORCID Icon,
Guido Kroemera Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;b Cell Biology and Metabolomics platforms, Gustave Roussy Cancer Campus, Villejuif, France;c UMR1138, INSERM, Paris, France;d Sorbonne Paris Cité, Université Paris Descartes, Paris, France;e Université Pierre et Marie Curie, Paris, France;g Center of Systems Medicine, Chinese Academy of Medical Science, Suzhou, China;h Pôle de Biologie, Hôpital Européen Georges Pompidou, Paris, France;i Karolinska Institutet, Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9334-4405
ORCID Icon &
Oliver Keppa Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France;b Cell Biology and Metabolomics platforms, Gustave Roussy Cancer Campus, Villejuif, France;c UMR1138, INSERM, Paris, France;d Sorbonne Paris Cité, Université Paris Descartes, Paris, France;e Université Pierre et Marie Curie, Paris, France;f Faculty of Medicine, Paris Sud/Paris XI University, Le Kremlin-Bicêtre, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6081-9558
ORCID Icon
Article: 1708126 | Received 09 Dec 2019, Accepted 19 Dec 2019, Published online: 28 Dec 2019

References

  • Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NCC, Berg T, Gisslinger B, Pietra D, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–3. doi:10.1056/NEJMoa1311347.
  • Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416–1430. doi:10.1056/NEJMoa1716614.
  • Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M, Villeval J-L, Raslova H, Kralovics R, Constantinescu SN, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127(10):1317–1324. doi:10.1182/blood-2015-11-679571.
  • Zhao L, Liu P, Boncompain G, Loos F, Lachkar S, Bezu L, Chen G, Zhou H, Perez F, Kepp O, et al. Identification of pharmacological inhibitors of conventional protein secretion. Sci Rep. 2018;8(1):14966. doi:10.1038/s41598-018-33378-y.
  • Han L, Schubert C, Köhler J, Schemionek M, Isfort S, Brümmendorf TH, Koschmieder S, Chatain N. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and golgi-mediated secretion. J Hematol Oncol. 2016;9(1):45.
  • Liu P, Zhao L, Loos F, Marty C, Xie W, Martins I, Lachkar S, Qu B, Waeckel-Énée E, Plo I, et al. Immunosuppression by mutated calreticulin released from malignant cells. Mol Cell. 2019. doi:10.1016/j.molcel.2019.11.004.
  • Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111.
  • Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, Martins I, Sukkurwala AQ, Michaud M, Senovilla L, et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev. 2013;24(4):311–318. doi:10.1016/j.cytogfr.2013.05.001.
  • Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat Commun. 2019;10(1):1486. doi:10.1038/s41467-019-09415-3.
  • Kepp O, Senovilla L, Kroemer G. Immunogenic cell death inducers as anticancer agents. Oncotarget. 2014;5(14):5190–5191. doi:10.18632/oncotarget.v5i14.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.